Kyverna Therapeutics, Inc. KYTX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $30.07M+0.2% | $30.01M-1.5% | $30.46M-15.0% | $35.82M-4.3% | $37.43M+11.8% | ||
| $11.29M+21.9% | $9.27M+12.1% | $8.27M-3.8% | $8.59M-13.8% | $9.98M+32.0% | ||
| $41.37M+5.3% | $39.28M+1.4% | $38.73M-12.8% | $44.41M-6.3% | $47.41M+15.5% | ||
| -$41.37M-5.3% | -$39.28M-1.4% | -$38.73M+12.8% | -$44.41M+6.3% | -$47.41M-15.5% | ||
| $667K+50.2% | $444K+6,243% | $7K-50.0% | $14K-44.0% | $25K-7.4% | ||
| $1.64M+10.9% | $1.48M-23.8% | $1.94M-16.7% | $2.33M-16.0% | $2.77M-21.9% | ||
| -$39.73M-5.1% | -$37.8M-2.8% | -$36.79M+12.6% | -$42.08M+5.7% | -$44.64M-19.1% | ||
| -$0.66+16.5% | -$0.79+7.1% | -$0.85+12.4% | -$0.97+5.8% | -$1.03-17.0% | ||
| -$41.02M-5.4% | -$38.91M-1.6% | -$38.31M+12.7% | -$43.9M+6.4% | -$46.91M-15.9% | ||
| -$41.37M-5.3% | -$39.28M-1.4% | -$38.73M+12.8% | -$44.41M+6.3% | -$47.41M-15.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Kyverna Therapeutics, Inc. profitable?
- Kyverna Therapeutics, Inc. is not currently profitable: it reported a net loss of $156.4M over the trailing twelve months.
- What is Kyverna Therapeutics, Inc.'s earnings per share?
- Kyverna Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-3.27.
- Where does Kyverna Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Kyverna Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.